Drug Profile
JHU 395
Alternative Names: CNS penetrating glutamine antagonist - Dracen Pharmaceuticals; JHU-395Latest Information Update: 22 Sep 2022
Price :
$50
*
At a glance
- Originator Dracen Pharmaceuticals
- Class Amines; Antineoplastics; Aza compounds; Caproates; Small molecules
- Mechanism of Action Apoptosis stimulants; Glutamine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Medulloblastoma; Neurofibrosarcoma
Most Recent Events
- 22 Sep 2022 Preclinical development is still ongoing for Medulloblastoma and Neurofibrosarcoma in USA (Dracen Pharmaceuticals website, September 2022)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Neurofibrosarcoma in USA (PO)
- 29 Jul 2021 Chemical structure information added